- Conditions
- Candidemia (systemic Candidiasis)
- Esophageal Candidiasis
- Activity
- Candida species (including those resistant to Azole Antifungals)
- Aspergillus species (some activity)
- Resistant organisms
- Cryptococcus species
- Trichosporon species
- Dimorphic Fungi (e.g. Coccidioides, Blastomyces, Histoplasma)
-
Echinocandin (Cyclic Lipopeptide)
- Inhibits synthesis of beta-(1,3)-D-Glucan a key cell wall component
- Semi-synthetic derived from the fermentation product of the fungue Aspergillus nidulans
- Candidemia (systemic Candidiasis)
- Load: 200 mg IV (infused at <1.1 mg/min) on day 1
- Next 100 mg IV (infused at <1.1 mg/min) daily for at least 14 days after the last positive culture
-
Esophageal Candidiasis
- Load: 100 mg IV (infused at <1.1 mg/min) on day 1
- Next 50 mg IV (infused at <1.1 mg/min) daily for at least 14 days (and at least 7 days after symptoms have resolved)
- Candidemia (systemic Candidiasis) for age 1 month and older
- Load: 3 mg/kg IV (infused at <1.1 mg/min) on day 1
- Next 1.5 mg/kg IV (infused at <1.1 mg/min) daily for at least 14 days after the last positive culture
- Well tolerated overall
- Similar adverse effects to Caspofungin and Micafungin
-
Anaphylaxis has occurred
-
Histamine reactions (Pruritus, Urticaria)
- Occurs with more rapid infusion (avoid infusion rates >1.1 mg/min)
- Unknown safety in Lactation
- Pregnancy Category C
- Teratogenic in animals (and insufficient data in humans)
- No renal dose adjustment needed
- Does not require dose adjustment in hepatic failure (unlike Caspofungin and Micafungin)
- No significant Drug Interactions
loading